IONS
Price
$42.15
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
6.72B
3 days until earnings call
XENE
Price
$30.30
Change
-$0.71 (-2.29%)
Updated
Jul 25 closing price
Capitalization
2.33B
11 days until earnings call
Interact to see
Advertisement

IONS vs XENE

Header iconIONS vs XENE Comparison
Open Charts IONS vs XENEBanner chart's image
Ionis Pharmaceuticals
Price$42.15
Change-$0.00 (-0.00%)
Volume$374
Capitalization6.72B
Xenon Pharmaceuticals
Price$30.30
Change-$0.71 (-2.29%)
Volume$969.94K
Capitalization2.33B
IONS vs XENE Comparison Chart in %
Loading...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IONS vs. XENE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (IONS: $42.15 vs. XENE: $30.30)
Brand notoriety: IONS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IONS: 0% vs. XENE: 83%
Market capitalization -- IONS: $6.72B vs. XENE: $2.33B
IONS [@Biotechnology] is valued at $6.72B. XENE’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IONS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IONS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IONS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • IONS’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than IONS.

Price Growth

IONS (@Biotechnology) experienced а +0.93% price change this week, while XENE (@Biotechnology) price change was -4.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

IONS is expected to report earnings on Jul 30, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.72B) has a higher market cap than XENE($2.33B). IONS YTD gains are higher at: 20.566 vs. XENE (-22.704). XENE has higher annual earnings (EBITDA): -290.36M vs. IONS (-357.21M). IONS has more cash in the bank: 2.15B vs. XENE (550M). XENE has less debt than IONS: XENE (8.68M) vs IONS (1.41B). IONS has higher revenues than XENE: IONS (717M) vs XENE (7.5M).
IONSXENEIONS / XENE
Capitalization6.72B2.33B289%
EBITDA-357.21M-290.36M123%
Gain YTD20.566-22.704-91%
P/E RatioN/AN/A-
Revenue717M7.5M9,560%
Total Cash2.15B550M390%
Total Debt1.41B8.68M16,254%
FUNDAMENTALS RATINGS
IONS vs XENE: Fundamental Ratings
IONS
XENE
OUTLOOK RATING
1..100
7387
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
10050
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
4586
P/E GROWTH RATING
1..100
695
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (74) in the Biotechnology industry is in the same range as IONS (96). This means that XENE’s stock grew similarly to IONS’s over the last 12 months.

XENE's Profit vs Risk Rating (50) in the Biotechnology industry is somewhat better than the same rating for IONS (100). This means that XENE’s stock grew somewhat faster than IONS’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as IONS (98). This means that XENE’s stock grew similarly to IONS’s over the last 12 months.

IONS's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for XENE (86). This means that IONS’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for IONS (69). This means that XENE’s stock grew somewhat faster than IONS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IONSXENE
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 5 days ago
63%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 7 days ago
69%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KLCIX20.500.12
+0.59%
Federated Hermes Kaufmann Large Cap IS
GCSSX25.600.14
+0.55%
Goldman Sachs Small Cap Eq Insghts Svc
RLEFX37.170.07
+0.19%
American Funds American Balanced R5E
RGSVX14.58-0.01
-0.07%
ClearBridge Global Infrastructure Inc IS
COCVX13.51-0.03
-0.22%
Columbia Overseas Value C

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
N/A
ALNY - IONS
59%
Loosely correlated
N/A
IDYA - IONS
53%
Loosely correlated
-1.33%
XENE - IONS
50%
Loosely correlated
-2.29%
IMVT - IONS
50%
Loosely correlated
-7.48%
BEAM - IONS
49%
Loosely correlated
+3.68%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-2.29%
IDYA - XENE
59%
Loosely correlated
-1.33%
CRNX - XENE
54%
Loosely correlated
N/A
ATXS - XENE
52%
Loosely correlated
+1.37%
DNLI - XENE
52%
Loosely correlated
-4.47%
NRIX - XENE
51%
Loosely correlated
-0.09%
More